# L4-TICK10-GI — Judge iter1 (Kimi K3, critic)

**Loop:** L4-TICK10-GI, iteration 1
**File reviewed (in full):** `src/content/comparisons/cagrisema-vs-tirzepatide.mdx`
**Implementer note:** `.planning/seo-engine/runs/2026-09-01/TICK10-GI.md` (explicitly "not a KEEP" — treated as claims to verify, not evidence)
**Bar:** LOOPS.md L4 — numbers on the page match the cited paper's published estimand; no identifier introduced that was not fetched this run.

## Independent verification performed

- **efetch (this review, not the implementer's):** `efetch.fcgi?db=pubmed&id=40544433,35658024,40544432&rettype=abstract&retmode=text` — all three abstracts read in full.
- **Topical match:** PMID 40544433 = REDEFINE 1 / NCT05567796 (NEJM 2025;393(7):635-647). PMID 40544432 = REDEFINE 2 / NCT05394519 (NEJM 2025;393(7):648-659). PMID 35658024 = SURMOUNT-1 / NCT04184622 (NEJM 2022;387(3):205-216). No sibling-trial mixup.
- **Select-String positive control:** pattern set `{40-45, 40–45, 20-25, 20–25, 55%, 2.3%, 22.7, 22-23, 22–23, 63%, 28.7, TRIUMPH, CagriSema}` — only `CagriSema` matched (33 lines). Zero hits on every banned string. Grep was not trusted alone.
- **git:** `git diff --stat HEAD` → `1 file changed, 29 insertions(+), 36 deletions(-)` on the existing comparison file. Modification, not a new slug.

## Criteria

| # | Criterion | Verdict | Evidence |
|---|---|---|---|
| 1 | Re-fetched 40544433 + 35658024 this run; page numbers match abstracts | **PASS** | I efetched both independently. Page −20.4% vs −3.0% (40544433 abstract: "−20.4% with cagrilintide-semaglutide as compared with −3.0% with placebo"). Page −20.9% vs −3.1% at 72 wk (35658024 abstract: "−20.9% (95% CI, −21.8 to −19.9) with 15-mg doses and −3.1% … with placebo"). |
| 2 | Nausea ~40-45% / vomiting ~20-25% / diarrhea / constipation GI range table stripped | **PASS** | Select-String: no `40-45`, `40–45`, `20-25`, `20–25` anywhere. Full read: Side Effect Profile now contains prose citing the class-level 79.6%/39.9%, no range table. |
| 3 | Discontinuation ~6-8% / ~10-12% range table stripped | **PASS** | Full read: no such ranges. Page states "This page does not quote a CagriSema discontinuation percent: that figure is not in the REDEFINE 1 PubMed abstract fetched 2026-09-02." Confirmed against abstract — no discontinuation % published. |
| 4 | REDEFINE 1 GI AE 79.6% vs 39.9% quoted from 40544433 | **PASS** | Abstract: "Gastrointestinal adverse events (affecting 79.6% in the cagrilintide-semaglutide group and 39.9% in the placebo group), including nausea, vomiting, diarrhea, constipation, or abdominal pain, were mainly transient and mild-to-moderate." Page line 185 matches verbatim in substance and correctly notes the symptoms are "named as a class, not as separate percents." |
| 5 | SURMOUNT-1 15 mg AE discontinuation 6.2% vs 2.6% quoted; no invented nausea splits | **PASS** | Abstract: "Adverse events caused treatment discontinuation in 4.3%, 7.1%, 6.2%, and 2.6% … 5-mg, 10-mg, and 15-mg … and placebo." Page attributes 6.2% to the 15 mg arm — correct arm assignment. Page explicitly declines to invent nausea/vomiting percents. |
| 6 | ≥20% ~55% / ≥25% ~35% / HbA1c −2.3% stripped; 57% (53–61) correct if kept; no invented REDEFINE 1 ≥20% | **PASS** | Select-String: no `55%`, no `2.3%`. Full read: no ≥25% row, no HbA1c row. Tirzepatide ≥20% kept as "57% (95% CI 53–61) vs 3% placebo" — exact match to abstract ("57% (95% CI, 53 to 61) … as compared with 3% (95% CI, 1 to 5)"). CagriSema cell says the abstract "does not publish the percent" — true (abstract reports P<0.001 likelihood only). REDEFINE 2 re-fetch confirms HbA1c reported as 73.5% vs 15.9% ≤6.5%, not a −2.3% delta; the invented delta is gone and not replaced. |
| 7 | ~$1,000/month Pricing row retained (TICK6-PRICE waits on Lucas) | **PASS** | Line 216: `\| **Pricing** \| Unknown \| ~$1,000/month \|`. Present. |
| 8 | No new URLs; OSA 63% / TRIUMPH 28.7% / 22.7% / 23%/25.5% not restored | **PASS** | git diff: modification of 1 existing file. Select-String: no `63%`, `28.7`, `TRIUMPH`, `22.7`, `22-23`, `22–23`. Full read: no 23%/25.5%; NCT06131437 quoted design-only with `hasResults` false as of 2026-09-02 — no head-to-head percent. |
| 9 | Estimands labeled; treatment-policy leads for REDEFINE | **PASS** | REDEFINE 1/2 labeled treatment-policy; SURMOUNT-1 labeled treatment-regimen (abstract: "The treatment-regimen estimand assessed effects regardless of treatment discontinuation"). Page adds a note that sponsor-quoted higher figures are the efficacy estimand — accurate framing, efficacy estimand not headlined. |
| 10 | Absence claims window-dated | **PASS** | "fetched 2026-09-02", "as of 2026-09-02" on the discontinuation absence and NCT06131437 hasResults claims. |

## Gaming check

The cheap ways to game this loop were: (a) strip aggressively past the brief — including the $1,000 row — to look maximally conservative; (b) swap invented numbers for vaguer but still unsourced claims; (c) quietly promote the efficacy estimand to make CagriSema look better; (d) declare self-KEEP. None occurred. The $1,000 row survives as instructed; every replacement sentence is tied to a fetched abstract and several explicitly state what the abstract does *not* publish (the strongest anti-invention posture this repo has); the estimand note downgrades rather than inflates CagriSema's headline; the implementer note is labeled "not a KEEP" and its declared "Not done" list (SURMOUNT-2/3/4 percents, SURPASS-CVOT HR, FAQ source counts not re-fetched) matches what I found — declared rather than hidden. The diff shape (−36/+29) is strip-and-cite, not bloat.

## Residuals (not fails — next loop candidates)

- SURMOUNT-2 −14.7%, SURMOUNT-3 −18.4%, SURPASS-CVOT HR 0.92 in this file were not re-fetched this increment (pre-existing; implementer declared). Future L4 tick should efetch 37385275 / 37840095 / 41406444 against these rows.
- FAQ "14 sources / 6 human studies" and "76 sources / 68 human studies" counts not re-census'd.
- REDEFINE 2 GI AE 72.5% vs 34.4% is in the fetched abstract but not on the page — optional addition, not required by the brief.

## Verdict

**KEEP.** All 10 criteria pass on independently fetched evidence. No invented percents, correct arm/estimand attribution, banned strings absent under positive-controlled search, no new URLs, instructed price row intact.
